Answers are grounded in this paper and cite their sources.
Patients with locally advanced esophageal carcinoma have consistently poor survival following surgery with associated high systemic and local-regional failure rates. Neoadjuvant therapeutic strategies have been employed in an attempt to improve outcome with variable success. Randomized trials of either neoadjuvant chemotherapy or chemoradiotherapy have shown conflicting results regarding survival and local-regional control. Future efforts should focus on identifying novel agents and targets to improve therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Hyngstrom et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: